Trial Profile
HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenstrom's macroglobulinemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOVON 124 WM; HOVON 124 WM/ECWM-R2
- 10 Apr 2024 This study has been completed in Greece, according to European Clinical Trials Database record.
- 13 Aug 2021 Primary endpoint has been met. (Primary Endpoint phase II: overall response rate (including CR, VGPR, PR and MR) after 8 cycles of ixazomib citrate, rituximab and dexamethasone, measured at 3 months after start of the last cycle (prior to the start of maintenance)) as per results published in the Journal of Clinical Oncology
- 13 Aug 2021 Results assessing combination of Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstrom's Macroglobulinemia published in the Journal of Clinical Oncology